GSK ovarian and womb cancer drug shows promise in early trial FemTech World
GSK (NYSE: GSK) reports Mo-Rez data in ovarian, endometrial cancer Stock Titan
Wonder drug for treating ovarian, womb cancer on the way NewsBytes
GSK posts encouraging data for endometrial and ovarian cancer drug London South East
Mitochondrial dysfunction has been demonstrated with a role in pathologically driving various obstetric and gynecological (OB/GYN) diseases, but molecular mediators associating mitochondrial dysfunction with discrete pathologies have not been determined …
Background/Objective: RNA modifications, including N6-methyladenosine (m6A), 5-methylcytosine (m5C), 7-methylguanosine (m7G), N1-methyladenosine (m1A), pseudouridine (Ψ), N4-acetylcytidine (ac4C), 5-methoxycarbonylmethyl-2-thiouridine (mcm5s2U) and adenosine-to-inosine (A-to-I) editing, constitute a critical layer of post-transcriptional regulation that …
GSK reports promising early results in ovarian and womb cancer drug trial The Guardian
SYS6043 Shows Initial Antitumor Activity in Pretreated Ovarian, Endometrial, and Cervical Cancer OncLive
Dr O'Cearbhaill on the Evaluation of REGN5668 in Recurrent Ovarian or Endometrial Cancer OncLive
Endometriosis-associated infertility is a complex condition in which the presence of endometrial-like tissue disrupts implantation and early pregnancy. Epigenetic regulators are critical for implantation and decidualization, yet their contribution to …